Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous abatacept in adults with active primary Sjögren's syndrome (Phase 3, randomized, double-blind, placebo-controlled)
2016-001948-19Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary Sjögren's syndrome comparing Abatacept with Placebo (2 arms). Primary endpoint: ESSDAI change from baseline to Day 169. Started Oct 2016; status: terminated.
02
Drugs
abatacept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2016-001948-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001948-19.